Education
About Us
Working with TipRanks
Follow Us
Jazz Pharmaceuticals (JAZZ)
NASDAQ:JAZZ
JAZZ Stock Chart & Stats
Day’s Range― - ―
52-Week Range$99.06 - $148.06
Previous CloseN/A
Volume75.28K
Average Volume (3M)1.14M
Market Cap
$8.43B
Enterprise Value$10.62B
Total Cash (Recent Filing)$2.41B
Total Debt (Recent Filing)$69.94M
Price to Earnings (P/E)15.9
Beta0.60
Next Earnings
Apr 30, 2025EPS Estimate
4.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.75
Shares Outstanding60,732,480
10 Day Avg. Volume1,250,877
30 Day Avg. Volume1,137,896
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)N/A
Price to Sales (P/S)2.07
Price to Cash Flow (P/CF)5.30
P/FCF Ratio5.30
Enterprise Value/Market Cap1.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.61
Enterprise Value/Ebitda8.52
Forecast
1Y Price Target
$193.82Price Target Upside39.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
---
Jazz Pharmaceuticals News
---
Bulls Say, Bears Say
Bulls Say
AcquisitionThe acquisition of Chimerix is expected to be highly accretive and bolster Jazz Pharmaceuticals' rare oncology portfolio.
Clinical TrialsThe Zani trial in gastric cancer is designed to demonstrate broad utility, which could be a key driver for future success.
ValuationJazz Pharmaceuticals is perceived to be undervalued compared to its peers, trading at a 40-55% discount, which presents a significant re-rating opportunity.
Bears Say
Deal UncertaintyIt is always challenging to comment on the likelihood of deal closures, implying some uncertainty in the transaction's finalization.
---
Ownership Overview
3.46% Insiders
29.63% Mutual Funds
34.94% Other Institutional Investors
4.57% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
JAZZ FAQ
What was Jazz Pharmaceuticals’s price range in the past 12 months?
Jazz Pharmaceuticals lowest stock price was $99.06 and its highest was $148.06 in the past 12 months.
What is Jazz Pharmaceuticals’s market cap?
Jazz Pharmaceuticals’s market cap is $8.43B.
When is Jazz Pharmaceuticals’s upcoming earnings report date?
Jazz Pharmaceuticals’s upcoming earnings report date is Apr 30, 2025 which is in 37 days.
How were Jazz Pharmaceuticals’s earnings last quarter?
Jazz Pharmaceuticals released its earnings results on Feb 25, 2025. The company reported $6.6 earnings per share for the quarter, beating the consensus estimate of $5.862 by $0.738.
Is Jazz Pharmaceuticals overvalued?
According to Wall Street analysts Jazz Pharmaceuticals’s price is currently Undervalued.
Does Jazz Pharmaceuticals pay dividends?
Jazz Pharmaceuticals does not currently pay dividends.
What is Jazz Pharmaceuticals’s EPS estimate?
Jazz Pharmaceuticals’s EPS estimate is 4.82.
How many shares outstanding does Jazz Pharmaceuticals have?
Jazz Pharmaceuticals has 60,732,480 shares outstanding.
What happened to Jazz Pharmaceuticals’s price movement after its last earnings report?
Jazz Pharmaceuticals reported an EPS of $6.6 in its last earnings report, beating expectations of $5.862. Following the earnings report the stock price went up 3.222%.
Which hedge fund is a major shareholder of Jazz Pharmaceuticals?
Currently, no hedge funds are holding shares in JAZZ
---
Jazz Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$193.82 (39.68% Upside)
$193.82 (39.68% Upside)
Blogger Sentiment
Bullish
JAZZ Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 11.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.6%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.81%
12-Months-Change
Fundamentals
Return on Equity
14.31%
Trailing 12-Months
Asset Growth
5.43%
Trailing 12-Months
Company Description
Jazz Pharmaceuticals
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
---
JAZZ Company Deck
---
JAZZ Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including record revenues, successful product launches, and strong sales growth for key products like Epidiolex. However, challenges such as the impact of pediatric protocol changes on Rylaze and potential revenue erosion from upcoming generic competition were noted. The company demonstrated financial strength by reducing debt and maintaining strategic flexibility.Read More>---
JAZZ Stock 12 Month Forecast
Average Price Target
$193.82
▲(39.68% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Neurocrine
―
Supernus Pharmaceuticals
―
Heron Therapeutics
―
SAGE Therapeutics
―
Best Analysts Covering JAZZ
1 Year
1 Year Success Rate
19/28 ratings generated profit
1 Year Average Return
+9.25%
reiterated a buy rating 19 days ago
Copying Annabel Samimy's trades and holding each position for 1 Year would result in 67.86% of your transactions generating a profit, with an average return of +9.25% per trade.
---